Published in Osteoporos Int on January 25, 2006
The clinical utility of bone marker measurements in osteoporosis. J Transl Med (2013) 1.21
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (1996) 11.60
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int (1994) 5.72
Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int (1995) 5.22
Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res (1996) 2.47
Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone (2000) 1.89
Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int (2005) 1.82
Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women. Osteoporos Int (1997) 1.71
How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int (1998) 1.70
Age-related decrements in bone mineral density in women over 65. J Bone Miner Res (1992) 1.69
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom (2004) 1.59
Degenerative diseases of the vertebral column. Radiology (1985) 1.43
What is the role of serial bone mineral density measurements in patient management? J Clin Densitom (2002) 1.25
A longitudinal study of the effect of spinal degenerative disease on bone density in the elderly. J Rheumatol (1995) 1.22
Technical principles of dual energy x-ray absorptiometry. Semin Nucl Med (1997) 1.12
Interobserver reproducibility of criteria for vertebral body exclusion. J Bone Miner Res (2004) 0.98
Technical standardization for dual-energy x-ray absorptiometry. J Clin Densitom (2004) 0.98
Which central dual X-ray absorptiometry skeletal sites and regions of interest should be used to determine the diagnosis of osteoporosis? J Clin Densitom (2002) 0.89
Use of the lowest vertebral body T-score to diagnose lumbar osteoporosis in men: is "cherry picking" appropriate? J Clin Densitom (2004) 0.83
Densitometric diagnosis of osteoporosis in men: effect of measurement site and normative database. J Clin Densitom (2002) 0.82
Factors influencing short-term precision of dual X-ray bone absorptiometry (DXA) of spine and femur. Calcif Tissue Int (1995) 0.77
The role of dual energy X-ray absorptiometry of lumbar spine and proximal femur in the diagnosis and follow-up of osteoporosis. Am J Med (1995) 0.77
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab (2004) 6.41
Mot1, a global repressor of RNA polymerase II transcription, inhibits TBP binding to DNA by an ATP-dependent mechanism. Genes Dev (1994) 3.45
Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev (1993) 2.82
Low vitamin D status despite abundant sun exposure. J Clin Endocrinol Metab (2007) 2.55
Dietary restriction and aging in rhesus monkeys: the University of Wisconsin study. Exp Gerontol (2000) 2.02
MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone (2004) 1.79
Role of the thymus in streptococcal cell wall-induced arthritis and hepatic granuloma formation. Comparative studies of pathology and cell wall distribution in athymic and euthymic rats. J Clin Invest (1985) 1.73
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet (1997) 1.64
Tumor-induced osteomalacia--unveiling a new hormone. N Engl J Med (1994) 1.61
NIH conference. Rheumatoid arthritis: evolving concepts of pathogenesis and treatment. Ann Intern Med (1984) 1.61
Lateral vertebral assessment: a valuable technique to detect clinically significant vertebral fractures. Osteoporos Int (2005) 1.47
Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J Clin Invest (1992) 1.45
Osteomalacia due to 1alpha,25-dihydroxycholecalciferol deficiency. Association with a giant cell tumor of bone. J Clin Invest (1977) 1.39
Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol (1998) 1.37
Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab (2008) 1.35
Hypophosphatemic osteomalacia: association with prostatic carcinoma. Ann Intern Med (1980) 1.32
Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults. J Clin Endocrinol Metab (2011) 1.25
Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J Clin Invest (1985) 1.24
Spontaneous production of fibroblast-activating factor(s) by synovial inflammatory cells. A potential mechanism for enhanced tissue destruction. J Exp Med (1985) 1.20
Altered activity of the nucleotide regulatory site in the parathyroid hormone-sensitive adenylate cyclase from the renal cortex of a patient with pseudohypoparathyroidism. J Clin Invest (1978) 1.17
Vitamin D and calcium levels in Ugandan adults with human immunodeficiency virus and tuberculosis. Int J Tuberc Lung Dis (2011) 1.11
Immune function in severe, active rheumatoid arthritis. A relationship between peripheral blood mononuclear cell proliferation to soluble antigens and synovial tissue immunohistologic characteristics. J Clin Invest (1984) 1.11
Mast cell numbers and histamine levels in synovial fluids from patients with diverse arthritides. Arthritis Rheum (1986) 1.10
1,25-Dihydroxycholecalciferol deficiency: the probable cause of hypocalcemia and metabolic bone disease in pseudohypoparathyroidism. J Clin Endocrinol Metab (1976) 1.09
Ontogeny of Phex/PHEX protein expression in mouse embryo and subcellular localization in osteoblasts. J Bone Miner Res (2002) 1.08
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol (1991) 1.08
Abnormal regulation of renal 25-hydroxyvitamin D-1 alpha-hydroxylase activity in the X-linked hypophosphatemic mouse. J Clin Invest (1983) 1.07
Mast cell numbers in rheumatoid synovial tissues. Correlations with quantitative measures of lymphocytic infiltration and modulation by antiinflammatory therapy. Arthritis Rheum (1987) 1.04
Genetic transmission of tumoral calcinosis: autosomal dominant with variable clinical expressivity. J Clin Endocrinol Metab (1985) 1.04
Stimulation of cartilage macromolecule synthesis by adenosine 3',5'-monophosphate. Biochim Biophys Acta (1976) 1.04
Normal calcitonin stimulation of serum calcitriol in patients with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab (1992) 1.03
Experiences from the Danish programme for eradication of bovine virus diarrhoea (BVD) 1994-1998 with special reference to legislation and causes of infection. Vet Microbiol (2000) 1.03
High affinity interaction of yeast transcriptional regulator, Mot1, with TATA box-binding protein (TBP). J Biol Chem (2001) 1.03
Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia. J Clin Invest (1980) 1.03
Purification and enzymic properties of Mot1 ATPase, a regulator of basal transcription in the yeast Saccharomyces cerevisiae. J Biol Chem (2000) 1.02
Coordinated maturational regulation of PHEX and renal phosphate transport inhibitory activity: evidence for the pathophysiological role of PHEX in X-linked hypophosphatemia. J Bone Miner Res (1999) 1.01
Osteomalacia after parathyroidectomy in patients with uremia. Ann Intern Med (1982) 1.01
Pathophysiology of X-linked hypophosphatemia, tumor-induced osteomalacia, and autosomal dominant hypophosphatemia: a perPHEXing problem. J Clin Endocrinol Metab (2001) 1.00
Calcification of entheses associated with X-linked hypophosphatemic osteomalacia. N Engl J Med (1985) 0.99
Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res (2001) 0.99
Effects of exercise on knee joints with osteoarthritis: a pilot study of biologic markers. Arthritis Care Res (1997) 0.98
Prediagnostic serum vitamin D and breast cancer. J Natl Cancer Inst (1998) 0.98
Adjustment for body mass index and calcitrophic hormone levels improves the diagnostic accuracy of the spot urine calcium-to-creatinine ratio. Osteoporos Int (2009) 0.97
Serum 1,25-dihydroxyvitamin D levels in subjects with X-linked hypophosphatemic rickets and osteomalacia. Calcif Tissue Int (1982) 0.97
The gene for X-linked hypophosphataemic rickets maps to a 200-300kb region in Xp22.1, and is located on a single YAC containing a putative vitamin D response element (VDRE). Hum Genet (1996) 0.96
Vitamin K supplementation reduces serum concentrations of under-gamma-carboxylated osteocalcin in healthy young and elderly adults. Am J Clin Nutr (2000) 0.96
Aluminum-induced neo-osteogenesis: a generalized process affecting trabecular networking in the axial skeleton. J Bone Miner Res (1990) 0.92
Parathyroid hormone effects on serum 1,25-dihydroxyvitamin D levels in patients with X-linked hypophosphatemic rickets: evidence for abnormal 25-hydroxyvitamin D-1-hydroxylase activity. J Clin Endocrinol Metab (1982) 0.92
Normocalcemic pseudohypoparathyroidism. Association with normal vitamin D3 metabolism. Am J Med (1979) 0.92
Multilocus mapping of the X-linked hypophosphatemic rickets gene. J Clin Endocrinol Metab (1992) 0.92
Induction of de novo bone formation in the beagle. A novel effect of aluminum. J Clin Invest (1988) 0.92
Deficient adenylate cyclase regulatory protein in renal membranes from a patient with pseudohypoparathyroidism. J Clin Invest (1983) 0.92
Effects of a new positioner on the precision of hip bone mineral density measurements. J Bone Miner Res (1997) 0.91
Stimulation of cartilage amino acid uptake by growth hormone-dependent factors in serum. Mediation by adenosine 3':5'-monophosphate. Biochim Biophys Acta (1975) 0.91
2MD, a new anabolic agent for osteoporosis treatment. Osteoporos Int (2006) 0.90
Immune function in severe, active rheumatoid arthritis: a relationship between peripheral blood mononuclear cell proliferation to soluble antigens and mononuclear cell subset profiles. J Immunol (1984) 0.90
X-Linked hypophosphatemic rickets: a disease often unknown to affected patients. Bone Miner (1994) 0.89
Aluminum deposition at the osteoid-bone interface. An epiphenomenon of the osteomalacic state in vitamin D-deficient dogs. J Clin Invest (1985) 0.89
The efficacy of vitamin D2 and oral phosphorus therapy in X-linked hypophosphatemic rickets and osteomalacia. J Clin Endocrinol Metab (1982) 0.89
Insulin-like growth factor-I regulation of renal 25-hydroxyvitamin D-1-hydroxylase activity. Endocrinology (1993) 0.89
Abnormal parathyroid hormone stimulation of 25-hydroxyvitamin D-1 alpha-hydroxylase activity in the hypophosphatemic mouse. Evidence for a generalized defect of vitamin D metabolism. J Clin Invest (1986) 0.89
Defective adenosine triphosphate synthesis. An explanation for skeletal muscle dysfunction in phosphate-deficient mice. J Clin Invest (1983) 0.88
Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis. Relationship to disease type, clinical activity, and antirheumatic therapy. Arthritis Rheum (1991) 0.87
Adenosine 3',5'-monophosphate effects on cartilage ribonucleic acid synthesis. Endocrinology (1979) 0.87
The role of abnormal vitamin D metabolism in X-linked hypophosphatemic rickets and osteomalacia. Adv Exp Med Biol (1984) 0.87
Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia. J Clin Endocrinol Metab (1993) 0.85
Measurement of 25-hydroxyvitamin D-1 alpha-hydroxylase activity in mammalian kidney. Anal Biochem (1983) 0.85
A YAC contig spanning the hypophosphatemic rickets disease gene (HYP) candidate region. Genomics (1994) 0.85
Abnormal parathyroid function in the X-linked hypophosphatemic mouse. Calcif Tissue Int (1985) 0.84
Comparison of phylloquinone bioavailability from food sources or a supplement in human subjects. J Nutr (1999) 0.84
Measurement of plasma adenosine 3',5'-monophosphate. J Clin Endocrinol Metab (1978) 0.84
Aluminum-induced mitogenesis in MC3T3-E1 osteoblasts: potential mechanism underlying neoosteogenesis. Endocrinology (1991) 0.83
Effect of intracarotid hyperosmolar mannitol on cerebral cortical arterioles--a morphometric study. Stroke (1984) 0.83
Normal phosphate transport in cells from the S2 and S3 segments of Hyp-mouse proximal renal tubules. Endocrinology (1996) 0.83
Calcitonin stimulation of renal 25-hydroxyvitamin D-1 alpha-hydroxylase activity in hypophosphatemic mice. Evidence that the regulation of calcitriol production is not universally abnormal in X-linked hypophosphatemia. J Clin Invest (1987) 0.83
Hypophosphatemic rickets/osteomalacia in linear sebaceous nevus syndrome: a variant of tumor-induced osteomalacia. J Pediatr (1986) 0.83
Phosphate transport in immortalized cell cultures from the renal proximal tubule of normal and Hyp mice: evidence that the HYP gene locus product is an extrarenal factor. J Bone Miner Res (1995) 0.83
Distribution of HLA class II alleles among Scandinavian patients with systemic lupus erythematosus (SLE): an increased risk of SLE among non[DRB1*03,DQA1*0501,DQB1*0201] class II homozygotes? Tissue Antigens (1992) 0.83
Impaired formation of beta-adrenergic receptor-nucleotide regulatory protein complexes in pseudohypoparathyroidism. J Clin Invest (1984) 0.82
Mast cell activation in human synovium explants by calcium ionophore A23187, compound 48/80, and rabbit IgG anti-human IgE, but not morphine sulfate. Inflamm Res (1996) 0.82
Flanking markers define the X-linked hypophosphatemic rickets gene locus. J Bone Miner Res (1993) 0.81
Symptomatic benign lymphoid hyperplasia of the terminal ileum in an adult. Am J Gastroenterol (1980) 0.81
Cyclosporin-A increases synthesis of 1,25-dihydroxyvitamin D3 in the rat and mouse. Endocrinology (1991) 0.81
Improved assessment of lumbar vertebral body strength using supine lateral dual-energy x-ray absorptiometry. J Bone Miner Res (1994) 0.81
Hypercalcemia and elevated calcitriol in a maintenance dialysis patient with tuberculosis. Arch Intern Med (1986) 0.81
Aluminum: culprit or accessory in the genesis of renal osteodystrophy. Semin Nephrol (1986) 0.81
Fasting and postprandial spot urine calcium-to-creatinine ratios do not detect hypercalciuria. Osteoporos Int (2011) 0.81
Abnormal adenosine 3'.5'-monophosphate stimulation of renal 1,25-dihydroxyvitamin D production in hyp mice: evidence that 25-hydroxyvitamin D-1 alpha-hydroxylase dysfunction results from aberrant intracellular function. Endocrinology (1989) 0.81
Inhibition of chondromucoprotein synthesis: an extraneuronal effect of nerve growth factor. J Pharmacol Exp Ther (1975) 0.80
The human glycine receptor: a new probe that is linked to the X-linked hypophosphatemic rickets gene. Genomics (1990) 0.80
Cholestatic hepatitis after ingestion of chaparral leaf: confirmation by endoscopic retrograde cholangiopancreatography and liver biopsy. J Clin Gastroenterol (1994) 0.80
Renal cyclic adenosine monophosphate: an accurate index of parathyroid function. Metabolism (1976) 0.80
Reduced renal cortical ribonucleoside triphosphate pools in three different hypophosphatemic animal models. Biochem Biophys Res Commun (1982) 0.80
Molecular dissection of Ca2+ efflux in immortalized proximal tubule cells. J Gen Physiol (1997) 0.80
Abnormal parathyroid hormone-related peptide stimulation of renal 25-hydroxyvitamin D-1-hydroxylase in Hyp mice: evidence for a generalized defect of enzyme activity in the proximal convoluted tubule. Endocrinology (1990) 0.79
Primary hyperparathyroidism in paraneoplastic hypercalcaemia. Lancet (1978) 0.79